(R)-(-)-Rolipram is primarily utilized in research and pharmaceutical development due to its potent and selective inhibition of phosphodiesterase-4 (PDE4). This enzyme plays a crucial role in regulating cyclic adenosine monophosphate (cAMP) levels, which are involved in various cellular processes. By inhibiting PDE4, it helps elevate cAMP levels, leading to anti-inflammatory and immunomodulatory effects. As a result, it has been extensively studied for its potential therapeutic applications in inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis. Additionally, its neuroprotective properties have sparked interest in its use for neurodegenerative disorders like Alzheimer's disease and depression. In preclinical studies, it has shown promise in enhancing memory and cognitive function, making it a candidate for treating cognitive impairments. Furthermore, its role in modulating cAMP signaling has also been explored in cancer research, particularly in understanding tumor growth and metastasis. Overall, (R)-(-)-Rolipram serves as a valuable tool in both therapeutic development and the study of cellular signaling pathways.